Drug General Information
Drug ID
D01LKO
Former ID
DNC008573
Drug Name
WFwGG-NH2
Drug Type
Small molecular drug
Indication Discovery agent Investigative [528740]
Structure
Download
2D MOL

3D MOL

Formula
C35H38N8O5
Canonical SMILES
C1=CC=C(C=C1)CC(C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NCC(=O)<br />NCC(=O)N)NC(=O)C(CC4=CNC5=CC=CC=C54)N
InChI
1S/C35H38N8O5/c36-26(15-22-17-38-27-12-6-4-10-24(22)27)33(46)42-29(14-21-8-2-1-3-9-21)35(48)43-30(34(47)41-20-32(45)40-19-31(37)44)16-23-18-39-28-13-7-5-11-25(23)28/h1-13,17-18,26,29-30,38-39H,14-16,19-20,36H2,(H2,37,44)(H,40,45)(H,41,47)(H,42,46)(H,43,48)/t26-,29+,30-/m1/s1
InChIKey
WIJADCOBFJYNSF-JJZPZGAKSA-N
PubChem Compound ID
Target and Pathway
Target(s) Growth hormone secretagogue receptor type 1 Target Info Inhibitor [528740]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
NetPath Pathway Leptin Signaling Pathway
Reactome Peptide ligand-binding receptors
G alpha (q) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 528740J Biol Chem. 2007 May 25;282(21):15799-811. Epub 2007 Mar 19.Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism.
Ref 528740J Biol Chem. 2007 May 25;282(21):15799-811. Epub 2007 Mar 19.Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.